retatrutide cagrilintide blend + – Research Peptide GLP-3 Retatrutide (24mg vials) -

Some companies have also developed oral and transdermal formulations of DSIP, although their efficacy and bioavailability compared to injectable forms have not been well-established

Purchase is restricted to individuals aged 21 or older for laboratory research use only

Under current Good Manufacturing Practice (cGMP) requirements, compounding pharmacies must source pharmaceutical-grade API from FDA-registered facilities that comply with applicable quality standards

Phase 3 readouts are landing on a rolling basis, but FDA approval has not happened as of June 2026

Overall, these findings support the use of cagrilintide-semaglutide as an add-on to basal insulin to improve glycemic control in patients with type 2 diabetes.